C. Ian Mockridge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
C. Ian Mockridge has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Ali Roghanian
Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK
1 shared publication - Anne Ljungars
BioInvent International AB, Lund, Sweden
1 shared publication Björn Frendeus
BioInvent International AB, Lund, Sweden
1 shared publication- Björn Hambe
BioInvent International AB, Lund, Sweden
1 shared publication - Charys Papagregoriou
Antibody & Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom
1 shared publication - Des C. Jones
Division of Immunology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 1 September 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (18)
LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation
Despite advances in identifying the key immunoregulatory roles of many of the human leukocyte immunoglobulin-like receptor (LILR) family members, the function of the inhibitory molecule LILRB3 (ILT5, CD85a, LIR3) remains unclear. Studies indicate a predominant myeloid expression; however, high homology within the LILR family and a relative paucity of reagents have hindered progress toward identifying the function of this receptor. To investigate its function and potential immunomodulatory capacity, a panel of LILRB3-specific monoclonal antibodies (mAbs) was generated. LILRB3-specific mAbs bound to discrete epitopes in Ig-like domain 2 or 4. LILRB3 ligation on primary human monocytes by an agonistic mAb resulted in phenotypic and functional changes, leading to potent inhibition of immune responses in vitro, including significant reduction in T cell proliferation. Importantly, agonizing LILRB3 in humanized mice induced tolerance and permitted efficient engraftment of allogeneic cells. Our findings reveal powerful immunosuppressive functions of LILRB3 and identify it as an important myeloid checkpoint receptor.
- 1 September 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (18)
Open AccessLILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation
Despite advances in identifying the key immunoregulatory roles of many of the human leukocyte immunoglobulin-like receptor (LILR) family members, the function of the inhibitory molecule LILRB3 (ILT5, CD85a, LIR3) remains unclear. Studies indicate a predominant myeloid expression; however, high homology within the LILR family and a relative paucity of reagents have hindered progress toward identifying the function of this receptor. To investigate its function and potential immunomodulatory capacity, a panel of LILRB3-specific monoclonal antibodies (mAbs) was generated. LILRB3-specific mAbs bound to discrete epitopes in Ig-like domain 2 or 4. LILRB3 ligation on primary human monocytes by an agonistic mAb resulted in phenotypic and functional changes, leading to potent inhibition of immune responses in vitro, including significant reduction in T cell proliferation. Importantly, agonizing LILRB3 in humanized mice induced tolerance and permitted efficient engraftment of allogeneic cells. Our findings reveal powerful immunosuppressive functions of LILRB3 and identify it as an important myeloid checkpoint receptor.